Geron (GERN) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 05/19/26
Geron Corporation (GERN) Presents at Bank of America Global Healthcare Conference 2026 TranscriptSeeking Alpha • 05/13/26
First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026GlobeNewsWire • 05/12/26
Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewsWire • 05/06/26
Geron Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate SecretaryGlobeNewsWire • 04/13/26
Geron to Participate in the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/06/26
Geron Corporation (GERN) Presents at Barclays 28th Annual Global Healthcare Conference TranscriptSeeking Alpha • 03/10/26
Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business HighlightsGlobeNewsWire • 02/25/26
Geron Plans to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026GlobeNewsWire • 02/11/26
Geron: Underpromise And Overdeliver Could Be The 2026 Strategy (Rating Upgrade)Seeking Alpha • 01/28/26
Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value CreationGlobeNewsWire • 12/11/25
Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO® (Imetelstat) in Lower-Risk MDSGlobeNewsWire • 12/08/25
Geron: Rytelo Launch Stalls Out, EU Partnership And IMpactMF Results Could HelpSeeking Alpha • 11/07/25